SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today reported positive data from a multicenter clinical study (NCT 04708951) comparing the adenoma detection rate (ADR) of its FDA-cleared G-EYE® balloon technology against ENDOCUFF VISION® (ECV) technology in patients undergoing screening or surveillance colonoscopy. Results from this randomized trial, the first head-to-head comparison of these two colonoscopy mechanical enhancement devices, showed that the ADR, particularly for advanced and large adenomas, was higher for the G-EYE® balloon than for the ECV attachment. Seth Gross, MD, Professor, Department of Medicine at NYU Grossman School of Medicine, Clinical Chief, Division of Gastroenterology and Hepatology at NYU Langone Health, and co-author on the abstract, presented the data in an oral session at ACG 2021, which is taking place October 22-27 in Las Vegas (ACG 2021, Presidential Plenary Session 1, Abstract #S233).
Trending
- Private equity owns less than 4% of U.S. hospitals, study finds (Medical Xpress)
- FIT Misses More CRCs in Women; Could Sex-Specific Thresholds Help? (HCP Live)
- Greg O’Grady: The Surgeon Who Left Surgery to Map the Stomach (Gut Health Times)
- GI Practices Lose More on Second Procedures Than Any Other Specialty, Jiro Health Benchmark Finds (PR Newswire)
- Throne Announces First Clinical Validation Study, Demonstrating Its AI-Powered Stool Classification Performs Comparably to Board-Certified Gastroenterologists (Business Wire)
- Blood-Based Colorectal Cancer Screening Averts More Deaths Than Stool Tests, Modeling Shows (Clinical Lab Products)
- For Better or Worse, Monitored Anesthesia Care Is Now the Default in GI Endoscopy (GI & Endoscopy News)
- AI ‘may offer an efficient way’ to detect colorectal neoplasia, but more research needed (Healio)
